Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Franco Stevanato
Pharma Pulse: Trump’s New Healthcare Roadmap, FDA Vaccine Warnings, and BPD to Lead The Agency Network
Commentary|Podcasts|January 16, 2026 In today’s Pharma Pulse, President Trump unveils a patient payment plan, the FDA flags a rare seizure risk for several leading flu vaccines, and MJH Life Sciences expands its data-driven reach. Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
Evaluate’s 2026 Pharma Forecast Signals Cautious Recovery, Rising M&A, and GLP-1 Market Shifts
Evaluate, known for providing market insights for the pharma sector, has recently unveiled its 2026 Preview report,1 which offers a 2026 market forecast. According to the report, biopharma has reclaimed momentum after a prolonged period of tight financing and limited investor support. However, it’s predicted that the industry will remain in a cautious recovery phase in 2026.
Premium Inflation Is Reshaping Patient Access and Adherence
Commentary|Videos|January 15, 2026 Author(s)Nicholas Saraceno, Senior Editor, Alan Balch, PhD In the first part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, how mounting financial pressure is forcing patients to ration care, undermining treatment adherence and accelerating downstream clinical and economic risk.
Pharma Pulse: Navigating the New Era of Healthcare
Commentary|Podcasts|January 15, 2026 In today’s Pharma Pulse, AbbVie joins TrumpRx, shingles vaccines reveal a longevity boost, and HER2 therapies break new ground in cancer treatment. Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines. First, AbbVie is joining the TrumpRx initiative.
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility
AbbVie has reached a deal with Trump administration to join TrumpRx, a direct-to-patient platform with a goal to drug prices in the United States, in exchange for exemption from pharma import tariffs and any future pricing mandates.1 Aside from offering lower prices in Medicaid, the company is also committing a total of $100 billion toward R&D and capital investments in the US over the next decade. This includes manufacturing efforts.
Pharma’s US Manufacturing Push Faces a Long Investment Horizon
According to Franco Stevanato, CEO of Stevanato Group, tariff policies are beginning to influence how pharmaceutical companies think about manufacturing location and supply chain resilience, but the shift toward localization will take time. While tariffs have created temporary cost pressures for the company, including surcharges passed on to customers, those impacts have largely been accepted by clients and are not yet driving immediate supply chain reconfiguration.
Pharma Pulse: Precision Cancer Care
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines. First, Novartis is scaling up treatment. The pharma giant has announced plans to build its fourth US-based radioligand therapy facility. This move is a massive bet on precision oncology.
Novartis to Build Fourth US Radioligand Therapy Facility to Strengthen Supply Chain
Novartis has revealed its intention to construct a new 35,000 square-foot radioligand therapy (RLT) product facility in Winter Park, FL, representing the fourth in the United States.1 The future plant is a component of the company’s greater mission of investing $23 billion over the next five years toward US infrastructure, while also serving as a way to strengthen the US pharma supply chain.
Managing Tariff-Driven Cost Increases Without Disrupting Customers
According to Franco Stevanato, CEO of Stevanato Group, tariff policies are beginning to influence how pharmaceutical companies think about manufacturing location and supply chain resilience, but the shift toward localization will take time. While tariffs have created temporary cost pressures for the company, including surcharges passed on to customers, those impacts have largely been accepted by clients and are not yet driving immediate supply chain reconfiguration.
Pharma Pulse: Amazon Pharmacy Sells Oral Wegovy, J&J’s Billion-Dollar Hub, and the Debt-Housing Crisis
Commentary|Podcasts|January 13, 2026 In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks. Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation.
Amazon Pharmacy Adds FDA-Approved Wegovy Pill, the First Oral GLP-1 for Weight Loss
Amazon Pharmacy has revealed that the recently FDA-approved Wegovy pill (oral semaglutide) is now available on its network.1 Novo Nordisk’s version of Wegovy in pill form represents the first-ever oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy that’s been approved for weight management. It also now marks the third formulation of Wegovy, expanding its available options.
Why US-Based Manufacturing Is Becoming a Strategic Imperative for Biopharma
According to Franco Stevanato, CEO of Stevanato Group, tariff policies are beginning to influence how pharmaceutical companies think about manufacturing location and supply chain resilience, but the shift toward localization will take time. While tariffs have created temporary cost pressures for the company, including surcharges passed on to customers, those impacts have largely been accepted by clients and are not yet driving immediate supply chain reconfiguration.
Pharma Pulse: J&J Enters TrumpRx and the Red Flags in Pediatric Vaccines
Commentary|Podcasts|January 12, 2026 In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines. Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
Johnson & Johnson Joins TrumpRx to Lower Drug Prices, Secures Tariff Exemption
Johnson & Johnson has reached a voluntary agreement with the Trump Administration to join TrumpRx, a direct-to-patient platform with a goal to lower US drug prices and align them with that of their European counterparts.1 In exchange for joining the program, J&J will be exempt from tariffs.
Franco Stevanato
Articles by Franco Stevanato In the first part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains how near-term tariff pressures are creating short-term headwinds while accelerating longer-term investment in regional manufacturing footprints—especially in the US.
Tariffs Nudge Pharma Toward Localization, but Supply Chains Can’t Shift Overnight
According to Franco Stevanato, CEO of Stevanato Group, tariff policies are beginning to influence how pharmaceutical companies think about manufacturing location and supply chain resilience, but the shift toward localization will take time. While tariffs have created temporary cost pressures for the company, including surcharges passed on to customers, those impacts have largely been accepted by clients and are not yet driving immediate supply chain reconfiguration.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Franco
Contact Franco, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack